Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

113.50 +17.69 (+18.46%)
Streaming Delayed Price Updated: 10:31 AM EDT, Jun 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,083,124
Open 106.66
Bid (Size) 113.00 (5)
Ask (Size) 113.50 (5)
Prev. Close 95.81
Today's Range 106.30 - 113.50
52wk Range 76.53 - 131.49
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bristol Myers Inks $11 Billion Licensing Pact With BioNTech For Bispecific Cancer Drug
BioNTech and Bristol Myers Squibb will co-develop BNT327 for solid tumors in a $1.5 billion deal with potential milestones totaling up to $7.6 billion. 
Via Benzinga
Bristol Myers To Pay Up To $11.1B To BioNTech To Co-Develop, Commercialize Investigational Cancer Drug
BMS will pay BioNTech $1.5 billion in an upfront payment in the second quarter and $2 billion in non-contingent anniversary payments through 2028. 
Via Stocktwits
Topics Government
Exposures Political

Performance

YTD
-1.6%
-1.6%
1 Month
+9.1%
+9.1%
3 Month
-3.0%
-3.0%
6 Month
-6.0%
-6.0%
1 Year
+20.6%
+20.6%

More News

Read More
Why Blueprint Medicines Shares Are Trading Higher By 27%; Here Are 20 Stocks Moving Premarket
Via Benzinga
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
From Bristol Myers Squibb
Via Business Wire
Earnings Scheduled For May 5, 2025
Via Benzinga
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
From BioNTech SE
Via GlobeNewswire
Robert F. Kennedy Jr. Says CDC Drops COVID Vaccine For 'Healthy' Pregnant Women, Children
Via Benzinga
Exposures COVID-19
BioNTech to Present Progress Across Diversified Oncology Pipeline at the 2025 ASCO Annual Meeting
From BioNTech SE
Via GlobeNewswire
FDA Limits Annual COVID-19 Boosters To High-Risk Americans, Demands New Trials For Healthy Adults In Policy Shift Under RFK Jr.
Via Benzinga
Exposures COVID-19 Product Safety
What's Going On With Vaccine Stocks Today?
Via Benzinga
The FDA Is Limiting Covid Shots. But Moderna, Vaccine Stocks Jumped.
Via Investor's Business Daily
Topics Bankruptcy Government
Exposures COVID-19 Financial Legal
Novavax Scores Key FDA Win, Shares Jump 19% As Sanofi Unlocks Milestone Payment
Via Benzinga
Exposures COVID-19 Product Safety
Novavax Wins Limited FDA Nod For COVID Shot—Cleared Only For Seniors, High-Risk Groups Amid Safety Scrutiny
Via Benzinga
Exposures COVID-19 Product Safety
Where BioNTech Stands With Analysts
Via Benzinga
Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio?
Via Benzinga
Market Monitor May 7 ( Hims & Hers Health, Upwork UP - Palantir, Monderna DOWN)
Via Chartmill
Why BioNTech Stock Got Trounced on Tuesday
Via The Motley Fool
Exposures COVID-19
BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion
Via Benzinga
BioNTech Announces First Quarter 2025 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
BioNTech Announces Appointment of Ramón Zapata to Management Board as Chief Financial Officer
From BioNTech SE
Via GlobeNewswire
Want Safe Dividend Income in 2025 and Beyond? Invest in the Following 3 Ultra-High-Yield Stocks.
Via The Motley Fool
Topics Bonds World Trade
Exposures COVID-19 Debt Markets Tariff
Trump-Era FDA Appointees Request New Trials For Novavax COVID Vaccine, Reportedly Delaying Approval Timeline
Via Benzinga
Topics Government
Exposures COVID-19 Political Product Safety
Why Is Summit Therapeutics Stock Trading Higher On Monday?
Via Benzinga
Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today
Via The Motley Fool
Exposures Product Safety
BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025
From BioNTech SE
Via GlobeNewswire

Frequently Asked Questions

Is BioNTech SE - American Depositary Shares publicly traded?
Yes, BioNTech SE - American Depositary Shares is publicly traded.
What exchange does BioNTech SE - American Depositary Shares trade on?
BioNTech SE - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for BioNTech SE - American Depositary Shares?
The ticker symbol for BioNTech SE - American Depositary Shares is BNTX on the Nasdaq Stock Market
What is the current price of BioNTech SE - American Depositary Shares?
The current price of BioNTech SE - American Depositary Shares is 113.50
When was BioNTech SE - American Depositary Shares last traded?
The last trade of BioNTech SE - American Depositary Shares was at 06/02/25 10:31 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.